替格瑞洛和氯吡咯雷抗血小板治疗急性冠脉综合征的临床疗效比较研究  

Comparison of clinical efficacy of Ticagrelor and Clopidogrel in the treatment of acute coronary syndrome

作　　者：吕萍[1] 毛桂玉 温连安[1] 

机构地区：[1]深圳市孙逸仙心血管医院药剂科,广东深圳518020

出　　处：《中国医药科学》2018年第2期27-29,共3页China Medicine And Pharmacy

摘　　要：目的探讨替格瑞洛和氯吡咯雷抗血小板治疗急性冠脉综合征的临床疗效,为急性冠脉综合征的临床治疗实践提供依据。方法选取我院心血管内科2015年12月～2017年2月期间临床收治的急性冠脉综合征患者288例为研究对象,采用随机数字表法将患者分成研究组和对照组,各144例。全部患者入院后均给予阿司匹林等常规基础治疗。同时,研究组患者给予替格瑞洛,首次剂量为180mg,以后剂量调整为90mg,2次/d;对照组患者给予氯吡格雷,首次剂量为300mg,以后剂量调整为75mg,1次/d。对两组患者的血小板聚集情况、心血管事件发生情况和不良反应发生情况进行观察和比较。结果 (1)研究组患者的血小板聚集率为(30.23±6.44)%,显著低于对照组的(40.77±7.32)%,组间比较差异有统计学意义(P<0.05);(2)研究组心血管事件发生率为7.64%,显著低于对照组的27.78%,组间比较差异有统计学意义(P<0.05);(3)研究组不良反应发生率与对照组水平基本相当,组间比较差异无统计学意义(P>0.05)。结论在临床治疗急性冠脉综合征的实践中,与氯吡咯雷相比,采用替格瑞洛抗血小板治疗的临床综合效果更好,安全性更高是临床治疗急性冠脉综合征的理想方案之一。Objective To investigate the clinical efficacy of Ticagrelor and clopidogrel in the treatment of acute coronary syndrome （ACS）,and to provide evidence for the clinical treatment of acs. Methods From December 2015 to February 2017,288 patients of cardiology patients with acute coronary syndrome of our hospital from were selected as the research object.They were divided into study group and control group by the random number table method. 144 cases in each group.All patients were given conventional treatment such as aspirin after admission.At the same time, the research group was treated with ticagrelor, the first dose of 180mg,after the dose was adjusted to 90mg,2 times/d; the control group were treated with clopidogrel,the first dose of 300mg,after the dose was adjusted to 75mg,1 times/d.The plate!et aggregation3he occurrence of cardiovascular events and adverse reactions were observed and compared between the two groups. Results （1） Patients in the study group, the platelet aggregation rate was （30.23＋6.44）%,significantly lower than the control group （40.77±7.32）%,the difference between groups Was significant （P 〈 0.05）;（2） The incidence rate of cardiovascular events of study group was 7.64%,significantly lower than the control group 27.78%,the difference between groups was significant （P 〈 0.05）;（3） The incidence of adverse reactions in the study group was basically equal to that of the control group, and there was no significant difference between the groups （P〉 0.05）. Conclusion The clinical practice in the treatment of acute coronary syndrome,compared with clopidogrel,with better clinical comprehensive therapeutic effect of ticagrelor antiplatelet,higher safety is one of the ideal reeimen for the treatment of acute coronary syndrome.

关 键 词：替格瑞洛 氯吡咯雷 抗血小板治疗 急性冠脉综合征 

分 类 号：R541.4[医药卫生—心血管疾病]